Shares of Moderna (MRNA Quick QuoteMRNA - Free Report) have gained 3% since the company announced third-quarter 2026 earnings on Nov. 6. While the increase seems modest in percentage terms, it added roughly $3 billion to the company’s market value.

The upside is a combination of better-than-expected Q3 results and an encouraging raise in its full-year revenue guidance. The improvement was mainly driven by stronger international sales of its COVID-19 vaccine, signaling that demand in overseas markets provided a much-needed boost to the company's performance.

Yet, investors should not base their investment decisions solely on the strength of a single quarter. It is important to assess whether Moderna can sustain its revenue momentum and strengthen its longer-term growth prospects.

Let's examine the company's financial performance, pipeline developments, growth opportunities and valuation to determine whether MRNA remains an attractive investment opportunity following its recent gains.

Oncology Emerges as a New Growth Pillar for Moderna

MRNA stock has been the best performer in the S&P 500 Index so far in 2026, primarily driven by positive phase III results on its personalized mRNA-based cancer therapy, intismeran autogene.

Developed in partnership with Merck (MRK Quick QuoteMRK - Free Report) , intismeran is central to Moderna’s expansion beyond vaccines. In August, Moderna announced positive top-line results from the phase III INTerpath-001 study in high-risk melanoma patients whose tumors had been removed through surgery. Detailed data reported last month showed that adding intismeran to Merck’s Keytruda reduced the risk of recurrence or death by 42% and distant metastasis or death by 38% compared with Keytruda alone. Based on these results, Moderna and Merck are working toward a regulatory submission before year-end 2026 and hope for approval in 2027.

The potential opportunity extends beyond melanoma. Moderna and Merck are also evaluating intismeran in nine phase II and phase III studies across several cancers, including non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma, among others. Positive results across these programs could broaden the therapy’s commercial potential and establish oncology as an important growth avenue beyond Moderna’s vaccine portfolio. However, realizing this opportunity will depend on further clinical progress, regulatory approvals and the eventual commercialization of the therapy.

Moderna is also exploring other approaches in oncology, which include cancer antigen therapies, T-cell engagers and cell-therapy enhancers. Earlier this month, the company reported preliminary data from a phase I/II study evaluating its T-cell engager candidate mRNA-2808 in heavily pretreated patients with relapsed or refractory multiple myeloma. Four confirmed responses, including two very good partial responses and two partial responses, were observed among 11 evaluable patients. Updated data from this study is expected at the American Society of Hematology annual meeting in December.

Partnerships Deals Boost MRNA’s Growth Prospects

Moderna has established long-term government partnerships in the UK, Canada and Australia, supporting vaccine sales outside the United States. The company also signed a five-year agreement with a local manufacturer in Mexico to expand its COVID-19 vaccine business. Such arrangements could provide greater revenue visibility and create opportunities to introduce additional products over time. International revenues reached approximately $900 million during the first nine months of 2026, exceeding the company's full-year 2025 international sales by $200 million. Supported by increased demand and international execution, management raised its 2026 revenue growth outlook to 15-25% from up to 10% previously.

The collaboration model also continues to support pipeline development by bringing in external funding, expertise and cost sharing. Moderna has agreements with large healthcare companies, including Merck, Recordati and Vertex, as well as organizations such as the Coalition for Epidemic Preparedness Innovations (“CEPI”). While the Recordati deal helps advance development of mRNA-3927, CEPI funding is helping advance the Bundibugyo ebolavirus (BDBV) vaccine candidate mRNA-1469.

Respiratory Vaccines Offer Diversification Benefits

Moderna’s respiratory business has evolved considerably from its origins as a COVID-19 vaccine franchise. The company has expanded into RSV with mResvia and, more recently, entered the seasonal influenza market with mFlusiva. It has also moved beyond standalone vaccines with its influenza/COVID-19 combination vaccine, approved in the EU as mCombriax and in Canada as mCoflu. Though commercial conversion is still early to judge, these additions give Moderna a presence across multiple respiratory vaccine categories and create opportunities to gradually diversify its revenue base.

Cash Burn Adds to MRNA’s Debt & Dilution Exposure

Despite ongoing cost-cutting efforts, Moderna's cash burn remains a concern. The company used $2.7 billion in operating cash during the first nine months of 2026, slightly lower than the $2.8 billion consumed a year earlier. Cash and investments stood at $8.0 billion as of Sept. 30, 2026, with liquidity supported by a $3.0 billion convertible-note offering in September. While the notes carry no regular interest and mature in March 2032, they add to the company's debt obligations and create the potential for shareholder dilution. Moderna also has $600 million drawn under a $1.5 billion credit facility with Ares Management Credit Funds, whose maturity was recently extended to 2031.

The company now expects to end 2026 with approximately $9 billion in total liquidity, including cash, investments and undrawn borrowing capacity. However, Moderna expects annual cash costs of approximately $4 billion to $4.5 billion from 2027 through 2030, primarily reflecting increased oncology investments. While the improved liquidity position provides financial flexibility to support pipeline development, continued cash consumption, substantial spending requirements and financing-related obligations remain concerns until Moderna achieves more sustainable cash generation.

Stiff Competition in Targeted Markets

Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE Quick QuotePFE - Free Report) /BioNTech (BNTX Quick QuoteBNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.

In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.

In oncology, the challenge is broader than competing for market share in a single indication. BioNTech is also developing an individualized mRNA-based cancer immunotherapy in collaboration with Roche, putting the two companies on a path to compete in the emerging personalized oncology market. As Moderna seeks to expand intismeran across multiple tumor types, its ability to differentiate the therapy, secure regulatory approvals and execute a successful commercial launch will be critical to realizing its potential.

MRNA Stock Performance, Valuation & Estimates

Year to date, MRNA stock has skyrocketed more than 743% compared with the industry’s 10% growth, as seen in the chart below. During this timeframe, the stock has also outperformed the broader Medical sector and the S&P 500 Index.

MRNA Stock Outperforms Industry, Sector & S&P 500

Image Source: Zacks Investment Research

From a valuation standpoint, Moderna appears to be trading at a significant premium compared to the industry. Based on the price/sales (P/S) ratio, the company’s shares currently trade at 37.97 times forward 12-month sales, higher than 2.00 times for the industry.

Image Source: Zacks Investment Research

Estimates for Moderna’s 2026 loss per share have improved from $8.31 to $7.35 in the past 7 days. The same for 2027 has narrowed from $4.46 to $3.73 during the same period.

Image Source: Zacks Investment Research

How to Play MRNA Stock?

Moderna currently carries a Zacks Rank #2 (Buy), supporting a positive view on the stock despite its sharp rally and premium valuation. While investors initially appeared concerned that the positive intismeran data had pushed the stock into overvalued territory, subsequent developments have strengthened the company's growth outlook. The encouraging early data on its T-cell engager candidate, combined with the increase in its 2026 revenue guidance, has raised expectations that Moderna's pipeline progress and expanding commercial opportunities could support future revenue growth and improve profitability.

Although MRNA trades at a significant premium based on its forward P/S ratio, an expanding oncology pipeline and growing respiratory vaccine portfolio offer potential growth opportunities that could justify the valuation, provided they translate into commercial success.

However, investors should remain mindful of the risks, including intense competition in respiratory vaccines and oncology, continued cash burn, potential shareholder dilution, and uncertainties surrounding clinical and regulatory outcomes. Moreover, following the stock's substantial rally this year, any setbacks in pipeline development or commercial execution could trigger significant volatility.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.